Author

Sergey V. Kulemzin

Observed names: Kulemzin, Sergey, S V Kulemzin, S. Kulemzin, S. V Kulemzin, S. V. Kulemzin, S.V. Kulemzin, Sergei Kulemzin, Sergey V. Kulemzin, Sergey Kulemzin, Sergey V Kulemzin, Кулемзин Сергей Викторович, С В Кулемзин, С. В. Кулемзин

Institutions: Institute of Molecular and Cell Biology, Siberian Branch of the Russian Academy of Sciences

Observed institutions: Russian Academy of Sciences, Novosibirsk State University, Lomonosov Moscow State University, Federal Almazov North-West Medical Research Centre, University of Alabama at Birmingham, Institute of Chemical Biology and Fundamental Medicine, Institute of Molecular and Cell Biology, Siberian Branch of the Russian Academy of Sciences

ORCID: 0000-0002-4706-623X

Observed ORCID: 0000-0002-4706-623X

OpenAlex ID: A5077439712

Evasion of the Innate Immune Response: the Old World Alphavirus nsP2 Protein Induces Rapid Degradation of Rpb1, a Catalytic Subunit of RNA Polymerase II

2012 · Ivan Akhrymuk, Sergey V. Kulemzin, et al. · Journal of Virology · 246

Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer

2019 · Andrey A. Gorchakov, Sergey V. Kulemzin, et al. · European Urology · 68

COVID-19. Etiology, pathogenesis, diagnosis and treatment

2020 · Vladimir Baklaushev, Sergey V Kulemzin, et al. · Journal of clinical practice · 55

FCRLA is a resident endoplasmic reticulum protein that associates with intracellular Igs, IgM, IgG and IgA

2010 · T. Santiago, S. V. Kulemzin, et al. · International Immunology · 40

Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials

2021 · Sergei Smirnov, Alexey Petukhov, et al. · Frontiers in Immunology · 34

Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern

2021 · Andrey A. Gorchakov, Sergey V. Kulemzin, et al. · Cell Discovery · 33

Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines

2019 · Sergey V. Kulemzin, Daria A. Matvienko, et al. · BMC Medical Genomics · 29

VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells

2018 · Sergey V. Kulemzin, Andrey A. Gorchakov, et al. · Oncotarget · 25

Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer

2020 · G. V. Kochneva, G. F. Sivolobova, et al. · Molecular Biology · 24

FCRL6 receptor: Expression and associated proteins

2010 · Sergey V. Kulemzin, Alina Y. Zamoshnikova, et al. · Immunology Letters · 22

Engineering Chimeric Antigen Receptors

2017 · S. V. Kulemzin, V. V. Kuznetsova, et al. · Acta Naturae · 21

Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo Restimulation

2022 · Maria G Byazrova, Sergey V Kulemzin, et al. · Frontiers in Immunology · 19

Functional Profiling of In Vitro Reactivated Memory B Cells Following Natural SARS-CoV-2 Infection and Gam-COVID-Vac Vaccination

2022 · Ekaterina A. Astakhova, Maria G. Byazrova, et al. · Cells · 18

Diversity of Immunoglobulin Light Chain Genes in Non-Teleost Ray-Finned Fish Uncovers IgL Subdivision into Five Ancient Isotypes

2018 · Sergey V. Guselnikov, Konstantin O. Baranov, et al. · Frontiers in Immunology · 16

shp-2 gene knockout upregulates CAR-driven cytotoxicity of YT NK cells

2020 · V. G. Subrakova, S. V. Kulemzin, et al. · Vavilov Journal of Genetics and Breeding · 15

The Activity of Human NK Cells Towards 3D Heterotypic Cellular Tumor Model of Breast Cancer

2025 · Anastasia Leonteva, Maria Abdurakhmanova, et al. · Cells · 10

Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies

2024 · Pavel P. Solodkov, Alexander M. Najakshin, et al. · Vaccines · 7

VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages

2022 · Sergey V. Kulemzin, Maria V. Sergeeva, et al. · Journal of Personalized Medicine · 7

Modular lentiviral vector system for chimeric antigen receptor design optimization

2017 · S. V. Kulemzin, N. A. Chikaev, et al. · Russian Journal of Bioorganic Chemistry · 7

CAR T-cell therapy: Balance of efficacy and safety

2017 · S. V. Kulemzin, V. V. Kuznetsova, et al. · Molecular Biology · 7

A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants

2024 · Sergey V. Guselnikov, Konstantin O. Baranov, et al. · Frontiers in Immunology · 6

Development and Characterization of Domain-Specific Monoclonal Antibodies Produced Against Human SLAMF9

2014 · Olga Volkova, Sergey Guselnikov, et al. · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · 6

Characterization of human FCRLA isoforms

2013 · Sergey Kulemzin, Nikolai Chikaev, et al. · Immunology Letters · 6

Hybrid Immunity from Gam-COVID-Vac Vaccination and Natural SARS-CoV-2 Infection Confers Broader Neutralizing Activity against Omicron Lineage VOCs Than Revaccination or Reinfection

2024 · Sergey V. Kulemzin, Sergey V. Guselnikov, et al. · Vaccines · 5

Comparative Pre-Clinical Analysis of CD20-Specific CAR T Cells Encompassing 1F5-, Leu16-, and 2F2-Based Antigen-Recognition Moieties

2023 · Tatyana Belovezhets, Sergey Kulemzin, et al. · International Journal of Molecular Sciences · 5

Works count: 60

Citation count: 764

H-index: 15

I10-index: 16